Skip to main content
Premium Trial:

Request an Annual Quote

Seahorse Bioscience Raises $5M in Private Financing

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Seahorse Bioscience yesterday said that it has raised $5 million in a Series D private financing.

The North Billerica, Mass.-based maker of cell analysis instruments said that it would use proceeds form the offering to expand its domestic and international sales and marketing efforts for its XF series analyzers for measuring cell metabolism.

Seahorse CEO Jay Teich called the financing "a milestone" for the firm. "We will use the funds to double our worldwide sales coverage and will be hiring at our manufacturing plant in Chicopee, [Mass.], ensuring that we keep pace with market demand for our XF system," he said in a statement.

Investors in this round included Commonwealth Capital Ventures, FLIR Systems Inc, Rock Maple Ventures, Life Sciences Partners, Oxford Bioscience Partners, Healthcare Ventures, New Science Ventures and HLM Venture Partners.

Filed under

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.